Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Entresto (valsartan / sacubitrilat): where help paying exists, what Medicare negotiated and what pharmacies pay
Medicare's negotiated price for a 30-day supply is $295 (in force since January 1, 2026). CMS's file lists all 14 packages of Entresto as deselected from the negotiation program, with the negotiated price ending December 31, 2026. After that date there is no negotiated price for them. The file does not say why. Per unit, the negotiated price is 45% of NADAC, the pharmacy acquisition benchmark. ClinicalTrials.gov lists 22 recruiting trials that name valsartan / sacubitrilat.
One package, side by side
Price per unit for one package of Entresto. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00078-0659-20 | ENTRESTO FCT 24MG/26MG 60 | EA | $5.23 | ends 2026-12-31 | $11.59 | 45% |
| 00078-0659-35 | ENTRESTO FCT 24MG/26MG 10X10 HUD | n/a | $5.23 | ends 2026-12-31 | n/a | no NADAC price |
| 00078-0659-61 | ENTRESTO FCT 24MG/26MG (blister) | n/a | $5.23 | ends 2026-12-31 | n/a | no NADAC price |
| 00078-0659-67 | ENTRESTO FCT 24MG/26MG 180 | EA | $5.23 | ends 2026-12-31 | $11.59 | 45% |
| 00078-0696-20 | ENTRESTO FCT 97MG/103MG 60 | EA | $5.23 | ends 2026-12-31 | $11.59 | 45% |
| 00078-0696-35 | ENTRESTO FCT 97MG/103MG 10X10 HUD | n/a | $5.23 | ends 2026-12-31 | n/a | no NADAC price |
| 00078-0696-61 | ENTRESTO FCT 97MG/103MG (blister) | n/a | $5.23 | ends 2026-12-31 | n/a | no NADAC price |
| 00078-0696-67 | ENTRESTO FCT 97MG/103MG 180 | EA | $5.23 | ends 2026-12-31 | $11.59 | 45% |
| 00078-0777-20 | ENTRESTO FCT 49MG/51MG 60 | EA | $5.23 | ends 2026-12-31 | $11.56 | 45% |
| 00078-0777-35 | ENTRESTO FCT 49MG/51MG 10X10 HUD | n/a | $5.23 | ends 2026-12-31 | n/a | no NADAC price |
| 00078-0777-61 | ENTRESTO FCT 49MG/51MG (blister) | n/a | $5.23 | ends 2026-12-31 | n/a | no NADAC price |
| 00078-0777-67 | ENTRESTO FCT 49MG/51MG 180 | EA | $5.23 | ends 2026-12-31 | $11.56 | 45% |
| 00078-1231-20 | ENTRESTO SPRINKLE 6MG/6MG ORAL PELLETS | EA | $5.52 | ends 2026-12-31 | $11.62 | 47% |
| 00078-1238-20 | ENTRESTO SPRINKLE 15MG/16MG ORAL PELLETS | EA | $5.65 | ends 2026-12-31 | $11.61 | 49% |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA207620 | Entresto Fct 24mg/26mg 180, Entresto Fct 24mg/26mg 60, Entresto Fct 49mg/51mg 180, Entresto Fct 49mg/51mg 60 and 2 more | May 9, 2036 | none listed | May 9, 2036 | patent 11058667; 24 dated entries listed |
| NDA218591 | Entresto Sprinkle 6mg/6mg Oral Pellets, Entresto Sprinkle 15mg/16mg Oral Pellets | February 2, 2037 | none listed | February 2, 2037 | patent 10722471; 6 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Entresto of $4.02 billion in 2024, across 3,898,804 claims and 795,291 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $4.02 billion | 3,898,804 | 795,291 | $1,031 |
| 2023 | $3.43 billion | 3,200,200 | 663,587 | $1,072 |
| 2022 | $2.49 billion | 2,527,550 | 520,839 | $985 |
| 2021 | $1.72 billion | 1,937,626 | 394,848 | $889 |
| 2020 | $1.20 billion | 1,502,171 | 283,074 | $801 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 5 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KY | 145 | $129,500 | Fee-for-service only |
| MO | 219 | $74,765 | All record types |
| NV | 66 | $72,461 | Fee-for-service only |
| MA | 82 | $54,856 | Fee-for-service only |
| IA | 68 | $38,121 | All record types |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (3 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 246 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated April 12, 2024 (Efficacy).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 22 interventional trials that name valsartan / sacubitrilat and are recruiting, and 7 more not yet recruiting. By phase: Phase 4: 8, Phase 3: 5, Not applicable: 3, Phase 1: 2, Phase 2: 2, PHASE1/PHASE2: 1, PHASE2/PHASE3: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT06693674 | Effect of Sacubitril-Valsartan on Cardiac Structure and FunctionCongenital Heart Disease | Phase 3 | Mayo Clinic | October 9, 2026 | United States |
| NCT07465653 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionHeart Failure With Reduced Ejection Fraction | Phase 1 | Novartis Pharmaceuticals | October 1, 2026 | United States, Canada |
| NCT07491718 | Manganese-enhanced Magnetic Resonance Imaging in Takotsubo CardiomyopathyTakotsubo Cardiomyopathy | Not applicable | University of Edinburgh | September 18, 2026 | United Kingdom |
| NCT07631156 | STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart FailureHeart Failure With Reduced Ejection Fraction; Heart Failure; Ventricular Dysfunction, Left | Phase 4 | Kyungsub Song | September 2, 2026 | South Korea |
| NCT07572032 | Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot StudyHeart Failure Due to Coronary Artery Disease; Valvular Cardiomyopathy; Heart Failure | Phase 4 | Kyungsub Song | September 2, 2026 | South Korea |
| NCT05508035 | The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection FractionHeart Failure With Moderately Reduced Ejection Fraction | Phase 3 | John Paul II Hospital, Krakow | July 31, 2026 | Poland |
| NCT04055428 | NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black IndividualsDiabetes Mellitus; Cardiovascular Diseases; Insulin Sensitivity/Resistance | Phase 2 | University of Alabama at Birmingham | July 28, 2026 | United States |
| NCT05194111 | Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/ValsartanHeart Failure; Heart Dysfunction | Phase 1 / Phase 2 | Virginia Commonwealth University | July 8, 2026 | United States |
| NCT06704633 | Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural TanzaniaHeart Failure | Phase 4 | Martin Rohacek | July 2, 2026 | Tanzania |
| NCT06655480 | Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEFHFpEF; LVDD; Myocardial Fibrosis | Phase 2 | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | April 24, 2026 | Russia |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Entresto?
For a 30-day supply the price CMS published is $295, in force since January 1, 2026. CMS's file lists all 14 packages of Entresto as deselected from the negotiation program, with the negotiated price ending December 31, 2026. After that date there is no negotiated price for them. The file does not say why. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 8 packages where both CMS files give a price per unit, the median negotiated price is 45% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Entresto?
No program in our finder lists this drug yet.
When could a generic version of Entresto arrive?
For Entresto, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA207620, May 9, 2036; NDA218591, February 2, 2037. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Entresto?
ClinicalTrials.gov lists 22 recruiting interventional trials that name valsartan / sacubitrilat (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Entresto?
CMS's Medicare Part D spending dataset reports gross spending on Entresto of $4.02 billion in 2024, across 3,898,804 claims and 795,291 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/entresto.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.